Frank Rimerman Advisors LLC Takes Position in Insulet Co. (NASDAQ:PODD)

Frank Rimerman Advisors LLC bought a new position in shares of Insulet Co. (NASDAQ:PODD) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 841 shares of the medical instruments supplier’s stock, valued at approximately $220,000.

Other large investors have also bought and sold shares of the company. SBI Securities Co. Ltd. bought a new position in Insulet during the 4th quarter worth $36,000. SRS Capital Advisors Inc. raised its position in Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 56 shares during the last quarter. Friedenthal Financial bought a new position in Insulet during the 4th quarter worth $57,000. TD Private Client Wealth LLC raised its position in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares during the last quarter. Finally, Assetmark Inc. raised its position in Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 246 shares during the last quarter.

Insider Buying and Selling

In related news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.47% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PODD. Stifel Nicolaus increased their price target on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Canaccord Genuity Group increased their price target on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Royal Bank of Canada assumed coverage on Insulet in a research note on Thursday, March 6th. They issued an “outperform” rating and a $340.00 target price for the company. Finally, JPMorgan Chase & Co. raised their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Price Performance

Insulet stock opened at $261.63 on Tuesday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market cap of $18.37 billion, a P/E ratio of 45.19, a P/E/G ratio of 3.62 and a beta of 1.29. The company’s 50 day moving average price is $272.40 and its two-hundred day moving average price is $255.72. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, equities analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.